Benjamin G. Vincent
A5020894945- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Colorectal Cancer Treatments and Studies
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Bladder and Urothelial Cancer Treatments
- Head and Neck Cancer Studies
- Hematopoietic Stem Cell Transplantation
- Spectroscopy and Laser Applications
- Single-cell and spatial transcriptomics
- Ferroptosis and cancer prognosis
- Reproductive System and Pregnancy
- Salivary Gland Tumors Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Nanoplatforms for cancer theranostics
- Cancer Cells and Metastasis
- Nanoparticle-Based Drug Delivery
- Pancreatic and Hepatic Oncology Research
- Head and Neck Surgical Oncology
- Immune cells in cancer
- Cancer Research and Treatments
University of North Carolina at Chapel Hill
2016-2025
UNC Lineberger Comprehensive Cancer Center
2015-2024
University of North Carolina Health Care
2015-2023
Palmetto Hematology Oncology
2022-2023
The University of Texas Health Science Center at Houston
2023
Segeberger Kliniken
2014-2022
Laboratoire d'Informatique, de Modélisation et d'Optimisation des Systèmes
2015-2020
Centre National de la Recherche Scientifique
2015-2020
Cone Health
2019
Laboratoire National des Champs Magnétiques Intenses
2019
We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled TCGA. Across types, we identified six immune subtypes—wound healing, IFN-γ dominant, inflammatory, lymphocyte depleted, immunologically quiet, and TGF-β dominant—characterized differences in macrophage or signatures, Th1:Th2 cell ratio, extent intratumoral heterogeneity, aneuploidy, neoantigen load, overall proliferation, expression immunomodulatory genes,...
Renal cell carcinoma (RCC) is not a single disease, but several histologically defined cancers with different genetic drivers, clinical courses, and therapeutic responses. The current study evaluated 843 RCC from the three major histologic subtypes, including 488 clear RCC, 274 papillary 81 chromophobe RCC. Comprehensive genomic phenotypic analysis of subtypes reveals distinctive features each subtype that provide foundation for development subtype-specific management strategies patients...
We studied 137 primary testicular germ cell tumors (TGCTs) using high-dimensional assays of genomic, epigenomic, transcriptomic, and proteomic features. These exhibited high aneuploidy a paucity somatic mutations. Somatic mutation only three genes achieved significance—KIT, KRAS, NRAS—exclusively in samples with seminoma components. Integrated analyses identified distinct molecular patterns that characterized the major recognized histologic subtypes TGCT: seminoma, embryonal carcinoma, yolk...
Highlights•An overview of PanCancer Atlas analyses on oncogenic molecular processes•Germline genome affects somatic genomic landscape in a pathway-dependent fashion•Genome mutations impact expression, signaling, and multi-omic profiles•Mutation burdens drivers influence immune-cell composition microenvironmentSummaryThe Cancer Genome (TCGA) has catalyzed systematic characterization diverse alterations underlying human cancers. At this historic junction marking the completion over 11,000...
Cancer cells can inhibit effector T (Teff) through both immunomodulatory receptors and the impact of cancer metabolism on tumor microenvironment. Indeed, Teff require high rates glucose metabolism, consumption essential nutrients or generation waste products by may impede cell metabolic pathways. Clear renal carcinoma (ccRCC) is characterized loss suppressor von Hippel-Lindau (VHL) altered metabolism. Here, we assessed how ccRCC influences activation primary patient infiltrating lymphocytes...
Background: Immune infiltration of the tumor microenvironment has been associated with improved survival for some patients solid tumors. The precise makeup and prognostic relevance immune infiltrates across a broad spectrum tumors remain unclear. Methods: Using mRNA sequencing data from Cancer Genome Atlas (TCGA) 11 types representing 3485 tumors, we evaluated lymphocyte macrophage gene expression by tissue type genomic subtypes defined within origin (Cox proportional hazards, Pearson...
There is tremendous interest in using immunotherapy to treat breast cancer, as evidenced by the more than 290 clinical trials ongoing at time of this narrative review. The objective review describe current status highlighting its potential both early-stage and metastatic disease.After searching ClinicalTrials.gov on April 24, 2018, PubMed up June 30, identify cancer trials, we found that immune checkpoint blockade (ICB) most investigated form cancer. Use ICB monotherapy has achieved...
We have profiled, for the first time, an evolving human metastatic microenvironment by measuring gene expression, matrisome proteomics, cytokine and chemokine levels, cellularity, extracellular matrix organization, biomechanical properties, all on same sample. Using biopsies of high-grade serous ovarian cancer metastases that ranged from minimal to extensive disease, we show how nonmalignant cell densities networks evolve with disease progression. Multivariate integration different...
Lymphocytic infiltration of tumors predicts improved survival in patients with breast cancer. Previous studies have suggested that this benefit is confined predominantly to the basal-like subtype. Immune ovarian also associated prognosis. Currently, it unclear what aspects immune response mediate outcome.Using The Cancer Genome Atlas mRNA-seq data and a large microarray dataset, we evaluated adaptive gene expression by genomic subtype To investigate B-cells observed be prognostic within...
Human endogenous retroviruses (hERVs) are remnants of exogenous that have integrated into the genome throughout evolution. We developed a computational workflow, hervQuant, which identified more than 3,000 transcriptionally active hERVs within The Cancer Genome Atlas (TCGA) pan-cancer RNA-Seq database. hERV expression was associated with clinical prognosis in several tumor types, most significantly clear cell renal carcinoma (ccRCC). explored two mechanisms by may influence immune...
For the past decade, cancer genomic studies have focused on mutations leading to splice-site disruption, overlooking those having splice-creating potential. Here, we applied a bioinformatic tool, MiSplice, for large-scale discovery of splice-site-creating (SCMs) across 8,656 TCGA tumors. We report 1,964 originally mis-annotated clear evidence creating alternative splice junctions. TP53 and GATA3 26 18 SCMs, respectively, ATRX has 5 from lower-grade gliomas. Mutations in 11 genes, including...
We report the discovery of a claudin-low molecular subtype high-grade bladder cancer that shares characteristics with homonymous breast cancer. Claudin-low tumors were enriched for multiple genetic features including increased rates RB1, EP300, and NCOR1 mutations; frequency EGFR amplification; decreased FGFR3, ELF3, KDM6A PPARG amplification. While showed highest expression immune gene signatures, they also demonstrated patterns consistent those observed in active immunosuppression. This...
Abstract Purpose: In high-grade serous ovarian cancer (HGSOC), higher densities of both B cells and the CD8+ T-cell infiltrate were associated with a better prognosis. However, precise role in antitumor response remains unknown. As peritoneal metastases are often responsible for relapse, our aim was to characterize immune HGSOC metastases. Experimental Design: Unmatched pre post-chemotherapy studied. B-cell localization assessed by immunostaining. Their cytokines chemokines measured...
Combination immunotherapy has recently emerged as a powerful cancer treatment strategy. A promising approach utilizes coadministration of antagonistic antibodies to block checkpoint inhibitor receptors, such antiprogrammed cell death-1 (aPD1), alongside agonistic activate costimulatory antitumor necrosis factor receptor superfamily member 4 (aOX40). Optimal T-cell activation is achieved when both immunomodulatory agents simultaneously engage T-cells and promote synergistic proactivation...
BACKGROUND. The KRAS proto-oncogene is among the most frequently mutated genes in cancer, yet for 40 years it remained an elusive therapeutic target. Recently, allosteric inhibitors that covalently bind to G12C mutations have been approved use lung adenocarcinomas. Although responses are observed, they often short-lived, thus making in-depth characterization of mechanisms resistance paramount importance.